Pars Journal of Medical Sciences

High level serum Inhibin-A in 1st and 2th pregnancy trimesters as a risk factor for adverse pregnancy outcomes: a systematic review and meta-analysis

Authors

1 Maternal-Fetal Medicine Research Center, Shiraz University of Medical Science, Shiraz, Iran

2 Infertility Research Center, Shiraz University of Medical Science, Shiraz, Iran

Abstract

Introduction: Naturaly; Inhibin-A plays an important role in the reproduction, and its abnormal level can be associated
with the risk of adverse pregnancy outcomes. The aim of the current study was to evaluate the effect of high level serum Inhibin-A in the first and second pregnancy trimesters on adverse pregnancy outcomes doing a systematic review and meta-analysis.
Material and Methods: In a systematic search done in PubMed, Embrace, Magiran, Irandoc, Web of Science, Scopus, and
Google Scholar in Persian and English languages since year 2000, seven articles were extracted and entered in the meta-analysis. Finally, odds ratio and confidence intervale were reported.
Results: The current meta-analysis showed that high level of Inhibin-A increased the odds of preeclampsia (OR=9.77, 95% C.I: 3.88-24.62); however, it did not affect on cesarean section delivery (OR= 1.06, 95% C.I: 0.80-1.41). As adverse pregnancy outcomes addressing the fetus and new born, high level of serum inhibin A incresed the odds of low birth weight (OR=7.34, 95% C.I: 4.4-12.23), preterm birth (OR=5.18, 95% C.I: 1.89-14.17), and fetal growth retardation (OR=2.77, 95% C.I: 1.78-4.30).
Conclusion: High level serum Inhibin-A in the first and second pregnancy trimesters increases the odds of preeclampsia, preterm birth, fetal growth retardation, and low birth weight; however, it does not effect on cesarean section.

Keywords

1. Alldred, S.K., et al., First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening. Cochrane Database of Systematic Reviews, 2017(3). 2. Kim, S.M., et al., Maternal serum placental growth factor combined with second trimester aneuploidy screening to predict small-for-gestation neonates without preeclampsia. Taiwanese Journal of Obstetrics and Gynecology, 2017. 56(6): p. 801-805. 3. Rodriguez, A., M.G. Tuuli, and A.O. Odibo, First-, Second-, and Third-Trimester Screening for Preeclampsia and Intrauterine Growth Restriction. Clin Lab Med, 2016. 36(2): p. 331-51. 4. Morris, R.K., et al., Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. BMC pregnancy and childbirth, 2008. 8(1): p. 33. 5. Wu, P., et al., Early pregnancy biomarkers in pre-eclampsia: a systematic review and meta-analysis. International journal of molecular sciences, 2015. 16(9): p. 23035-23056. 6. Allen, R.E., et al., Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2014. 182: p. 194-201. 7. Singnoi, W., et al., A cohort study of the association between maternal serum Inhibin-A and adverse pregnancy outcomes: a population-based study. BMC pregnancy and childbirth, 2019. 19(1): p. 124. 8. Neuman, R.I., et al., PAPP‐A2 and Inhibin A as Novel Predictors for Pregnancy Complications in Women With Suspected or Confirmed Preeclampsia. Journal of the American Heart Association, 2020. 9: p. e018219. 9. Yue, C.Y., et al., Are serum levels of inhibin A in second trimester predictors of adverse pregnancy outcome? PLoS One, 2020. 15(5): p. e0232634. 10. GA Wells, B.S., D O'Connell, J Peterson, V Welch, M Losos, P Tugwell,, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2018. 11. Singnoi, W., et al., A cohort study of the association between maternal serum Inhibin-A and adverse pregnancy outcomes: a population-based study. 2019. 19(1): p. 124. 12. Yu, J., et al., Inhibin A, activin A, placental growth factor and uterine artery Doppler pulsatility index in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol, 2011. 37(5): p. 528-33. 13. Tul, N., et al., Predicting complications of pregnancy with first‐trimester maternal serum free‐βhCG, PAPP‐A and inhibin‐A. Prenatal Diagnosis: Published in Affiliation with the International Society for Prenatal Diagnosis, 2003. 23(12): p. 990-996. 14. Jelliffe‐Pawlowski, L., et al., Maternal characteristics and mid‐pregnancy serum biomarkers as risk factors for subtypes of preterm birth. BJOG: An International Journal of Obstetrics & Gynaecology, 2015. 122(11): p. 1484-1493. 15. Yue, C.-Y., et al., Are serum levels of inhibin A in second trimester predictors of adverse pregnancy outcome? Plos one, 2020. 15(5): p. e0232634. 16. Metcalfe, A., et al., Prediction of obstetrical risk using maternal serum markers and clinical risk factors. Prenatal diagnosis, 2014. 34(2): p. 172-179. 17. Alimohammadi, S., et al., Relationship between Serum Inhibin A and Pregnancy Outcomes. Avicenna Journal of Clinical Medicine, 2020. 27(1): p. 30-36. 18. Kim, S.M., et al., Maternal serum placental growth factor combined with second trimester aneuploidy screening to predict small-for-gestation neonates without preeclampsia. Taiwan J Obstet Gynecol, 2017. 56(6): p. 801-805. 19. Yazdani, S., et al., Correlation of pregnancy outcome with quadruple screening test at second trimester. Medical journal of the Islamic Republic of Iran, 2015. 29: p. 281. 20. Broumand, F., et al., A study of the diagnostic value of Inhibin A Tests for occurrence of preeclampsia in pregnant women. Electron Physician, 2018. 10(1): p. 6186-6192. 21. Wu, P., et al., Early Pregnancy Biomarkers in Pre-Eclampsia: A Systematic Review and Meta-Analysis. International journal of molecular sciences, 2015. 16(9): p. 23035-23056. 22. Allen, R.E., et al., Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis. Eur J Obstet Gynecol Reprod Biol, 2014. 182: p. 194-201. 23. Florio, P., et al., Activin A, inhibin A, inhibin B and parturition: changes of maternal and cord serum levels according to the mode of delivery. Br J Obstet Gynaecol, 1999. 106(10): p. 1061-5. 24. Huang, S.Y., et al., Is maternal serum inhibin A a good predictor in preterm labor? - Experience from a community hospital in Taiwan. Biomed J, 2020. 43(2): p. 183-188. 25. Plevyak, M.P., et al., Concentrations of serum total activin A and inhibin A in preterm and term labor patients: a cross-sectional study. J Soc Gynecol Investig, 2003. 10(4): p. 231-6.